Deutsche Bank AG grew its position in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 4.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 209,854 shares of the medical instruments supplier’s stock after buying an additional 9,437 shares during the quarter. Deutsche Bank AG owned 0.28% of West Pharmaceutical Services worth $20,702,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in WST. Alps Advisors Inc. purchased a new position in shares of West Pharmaceutical Services in the 4th quarter valued at about $206,000. First Republic Investment Management Inc. purchased a new position in shares of West Pharmaceutical Services in the 4th quarter valued at about $211,000. Private Advisor Group LLC purchased a new position in shares of West Pharmaceutical Services in the 3rd quarter valued at about $202,000. Stephens Inc. AR purchased a new position in shares of West Pharmaceutical Services in the 3rd quarter valued at about $210,000. Finally, Tiedemann Wealth Management LLC purchased a new position in shares of West Pharmaceutical Services in the 3rd quarter valued at about $207,000. Institutional investors own 94.37% of the company’s stock.
WST stock opened at $86.13 on Friday. The company has a current ratio of 2.66, a quick ratio of 1.89 and a debt-to-equity ratio of 0.15. West Pharmaceutical Services Inc. has a twelve month low of $77.97 and a twelve month high of $103.36. The firm has a market cap of $6,658.79, a PE ratio of 43.28, a price-to-earnings-growth ratio of 2.30 and a beta of 1.15.
West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, February 15th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. West Pharmaceutical Services had a net margin of 9.42% and a return on equity of 14.68%. The firm had revenue of $415.60 million during the quarter, compared to the consensus estimate of $416.90 million. During the same period last year, the firm posted $0.54 EPS. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. equities research analysts anticipate that West Pharmaceutical Services Inc. will post 2.85 earnings per share for the current fiscal year.
West Pharmaceutical Services declared that its board has authorized a stock buyback plan on Thursday, February 15th that allows the company to buyback 800,000 shares. This buyback authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 2nd. Shareholders of record on Wednesday, April 18th will be issued a dividend of $0.14 per share. The ex-dividend date of this dividend is Tuesday, April 17th. This represents a $0.56 annualized dividend and a yield of 0.65%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 28.14%.
A number of equities analysts have recently issued reports on WST shares. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Goldman Sachs assumed coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 24th. They set a “neutral” rating and a $110.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $108.17.
TRADEMARK VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/24/deutsche-bank-ag-has-20-70-million-holdings-in-west-pharmaceutical-services-inc-wst.html.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.